Migraine patients can now try three new drugs for prevention

October 10, 2018 by Stacey Burling, The Philadelphia Inquirer
Credit: CC0 Public Domain

Until this year, migraine sufferers had to make do with drugs originally developed for other medical conditions, such as high blood pressure or depression. Now, there are three new drugs that were developed just for preventing the horrible headaches.

Erenumab (Aimovig) was approved by the FDA in May. Fremanezumab (Ajovy) was approved in September and is now available. Galcanezumab (Emgality) was approved late in September and recently began arriving in doctors' offices.

"They have a lot of promise and are potentially very important," said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for who have not responded to other treatments, but Hamilton said that what is "potentially even more clinically relevant is they have a lower side-effect profile" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.

Stephen Silberstein, director of the Jefferson Headache Center, said about 800 of his migraine patients are on a list to start taking the drugs. He was involved in testing erenumab and helped design and run the trial for fremanezumab, so many of his patients were involved in the clinical trials and have already tried the medicines.

Silberstein said insurance is expected to offset erenumab's price tag, about $600 a month, but patients will be eligible only if they have tried other drugs first and found they didn't help. He and Hamilton said some other migraine drugs have similar costs.

Louis Colburn, 71, a retired police officer and security manager who gets migraines most days of the week, was among the first of Silberstein's patients to try fremanezumab. His headaches, he said, are "just like somebody's got a drill inside your brain." He watched calmly last week as nurse practitioner Rachel Seligman emptied three syringes under the skin of his left thigh.

The shots should last three months. Silberstein said Colburn should see results in a week. He expects that patients with frequent headaches won't mind getting three shots at once. "If you realized how bad a migraine headache is, the shots don't matter," he said.

Migraines affect 40 million people in the United States. These drugs were tested in people with chronic migraines, defined as 15 or more headaches a month. One to 2 percent of the population falls into that category.

The are monoclonal antibodies aimed at CGRP (calcium-gene-related peptide), a string of amino acids that play a role in how people experience pain, and must be injected. All can be taken monthly, but fremanezumab has the advantage of also having the option of quarterly shots. The drugs have different mechanisms, but they prevent CGRP from working normally. Another that targets CGRP and will be given intravenously is in development, Silberstein said.

Competition may bring costs down, he said.

CGRP is elevated during . It also is involved in the movement of food through the gut and is present in the heart and blood vessels. Researchers were concerned that the drugs might cause systemic problems, but Silberstein said mild constipation was the most serious side effect of the drugs in the trials.

He said the drugs appeared to be equally effective. About half the patients had a 50 percent or greater reduction in the number of headaches they experienced. Almost three-quarters had at least a 30 percent reduction. The overall averages look less exciting, however. Chronic patients had about two fewer days a month than those who took placebos. The placebo group had a small reduction in headaches, too. In the treatment groups, the intensity of the headaches also went down.

Silberstein said the drugs were helpful for patients who responded. "I've had patients already on these drugs who went from not being able to function to having almost a normal life," he said.

Explore further: The burden of the 'suicide' headache


Related Stories

The burden of the 'suicide' headache

September 4, 2018
They're called suicide headaches because the pain is frequent and unbearable.

Several new medications in the pipeline to prevent migraine

June 13, 2017
(HealthDay)—A host of new medications that appear to prevent migraine headaches are in the final stages of testing and approval in the United States, according to a presentation at the annual meeting of the American Headache ...

Another drug to prevent migraines shows promise

May 29, 2018
(HealthDay)—Migraine sufferers could soon turn to a number of new medications to avoid their crippling headaches.

When others fail, new migraine treatment may work

April 17, 2018
People who have tried unsuccessfully to prevent migraine with other treatments may find relief with a drug called erenumab, according to a preliminary study released today that will be presented at the American Academy of ...

New, long-acting drugs cut frequency of migraine headaches

November 30, 2017
New, long-acting drugs may hold hope for millions of people who often suffer migraines. Studies of two of these medicines, given as shots every month or so, found they cut the frequency of the notoriously painful and disabling ...

FDA approves first drug aimed at preventing migraines

May 18, 2018
(HealthDay)—The millions of Americans who suffer from migraine may have a new source of hope—the first drug aimed at preventing the headaches gained U.S. Food and Drug Administration approval on Thursday.

Recommended for you

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

Infectivity of different HIV-1 strains may depend on which cell receptors they target

December 6, 2018
Distinct HIV-1 strains may differ in the nature of the CCR5 molecules to which they bind, affecting which cells they can infect and their ability to enter cells, according to a study published December 6 in the open-access ...

Protecting cell powerhouse paves way to better treatment of acute kidney injury

December 6, 2018
For the first time, scientists have described the body's natural mechanism for temporarily protecting the powerhouses of kidney cells when injury or disease means they aren't getting enough blood or oxygen.

New study uncovers why Rift Valley fever is catastrophic to developing fetuses

December 5, 2018
Like Zika, infection with Rift Valley fever virus can go unnoticed during pregnancy, all the while doing irreparable—often lethal—harm to the fetus. The results of a new study, led by researchers at the University of ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.